Local administration of CpG-STAT3 antisense oligonucleotides (inhibiting STAT3 and activating TLR9) has been shown to induce systemic antitumor effects in two genetically modified mouse models of PC, by decreasing PD-L1 [129]. The gene discussed is TLR9; the disease is pachyonychia congenita.